Skip to main content
Top
Published in: Inflammopharmacology 4/2023

Open Access 08-05-2023 | Arterial Occlusive Disease | Original Article

Oridonin attenuates the progression of atherosclerosis by inhibiting NLRP3 and activating Nrf2 in apolipoprotein E-deficient mice

Authors: Lei Wang, Xiaoqi Zhao, Jiawen Ding, Yutong Liu, Han Liu, Lei Zheng, Hongting Zhao, Zichen Sun, Kuanyu Li, Jing Cai, Tong Qiao

Published in: Inflammopharmacology | Issue 4/2023

Login to get access

Abstract

Oridonin, a well-known traditional Chinese herbal medicinal product isolated from Isodon rubescens (Hemsl.) H.Hara, has many potential properties, including anti-inflammatory and antioxidant activities. However, there is no evidence whether oridonin have a protective effect on atherosclerosis. This study focused on the effects of oridonin on oxidative stress and inflammation generated from atherosclerosis. The therapeutic effect on atherosclerosis was evaluated by intraperitoneal injection of oridonin in a high-fat fed ApoE−/− mouse model. We isolated mouse peritoneal macrophages and detected the effect of oridonin on oxidized low-density lipoprotein-induced lipid deposition. Oil red O staining, Masson's staining, dihydroethidium fluorescence staining, immunohistochemical staining, western blotting analysis, immunofluorescence, enzyme-linked immunosorbent assay and quantitative real-time PCR were used to evaluate the effect on atherosclerosis and explore the mechanisms. Oridonin treatment significantly alleviated the progression of atherosclerosis, reduced macrophage infiltration and stabilized plaques. Oridonin could significantly inhibit inflammation associated with NLRP3 activation. Oridonin significantly reduced oxidative stress by blocking Nrf2 ubiquitination and degradation. We also found that oridonin could prevent the formation of foam cells by increasing lipid efflux protein and reducing lipid uptake protein in macrophages. Oridonin has a protective effect on atherosclerosis in ApoE−/− mice, which may be related to the inhibition of NLRP3 and the stabilization of Nrf2. Therefore, oridonin may be a potential therapeutic agent for atherosclerosis.
Literature
go back to reference Chen L, Yao Q, Xu S, Wang H, Qu P (2018) Inhibition of the NLRP3 inflammasome attenuates foam cell formation of THP-1 macrophages by suppressing ox-LDL uptake and promoting cholesterol efflux. Biochem Biophys Res Commun 495(1):382–387CrossRefPubMed Chen L, Yao Q, Xu S, Wang H, Qu P (2018) Inhibition of the NLRP3 inflammasome attenuates foam cell formation of THP-1 macrophages by suppressing ox-LDL uptake and promoting cholesterol efflux. Biochem Biophys Res Commun 495(1):382–387CrossRefPubMed
go back to reference Du Y, Villeneuve NF, Wang X-J, Sun Z, Chen W, Li J, Lou H, Wong PK, Zhang DD (2008) Oridonin confers protection against arsenic-induced toxicity through activation of the Nrf2-mediated defensive response. Environ Health Perspect 116(9):1154–1161CrossRefPubMedPubMedCentral Du Y, Villeneuve NF, Wang X-J, Sun Z, Chen W, Li J, Lou H, Wong PK, Zhang DD (2008) Oridonin confers protection against arsenic-induced toxicity through activation of the Nrf2-mediated defensive response. Environ Health Perspect 116(9):1154–1161CrossRefPubMedPubMedCentral
go back to reference Edsfeldt A, Swart M, Singh P, Dib L, Sun J, Cole JE, Park I, Al-Sharify D, Persson A, Nitulescu M, Borges PDN, Kassiteridi C, Goddard ME, Lee R, Volkov P, Orho-Melander M, Maegdefessel L, Nilsson J, Udalova I, Goncalves I, Monaco C (2022) Interferon regulatory factor-5-dependent CD11c+ macrophages contribute to the formation of rupture-prone atherosclerotic plaques. Eur Heart J 43(19):1864–1877CrossRefPubMedPubMedCentral Edsfeldt A, Swart M, Singh P, Dib L, Sun J, Cole JE, Park I, Al-Sharify D, Persson A, Nitulescu M, Borges PDN, Kassiteridi C, Goddard ME, Lee R, Volkov P, Orho-Melander M, Maegdefessel L, Nilsson J, Udalova I, Goncalves I, Monaco C (2022) Interferon regulatory factor-5-dependent CD11c+ macrophages contribute to the formation of rupture-prone atherosclerotic plaques. Eur Heart J 43(19):1864–1877CrossRefPubMedPubMedCentral
go back to reference Fuhrman B, Volkova N, Aviram M (2002) Oxidative stress increases the expression of the CD36 scavenger receptor and the cellular uptake of oxidized low-density lipoprotein in macrophages from atherosclerotic mice: protective role of antioxidants and of paraoxonase. Atherosclerosis 161(2):307–316CrossRefPubMed Fuhrman B, Volkova N, Aviram M (2002) Oxidative stress increases the expression of the CD36 scavenger receptor and the cellular uptake of oxidized low-density lipoprotein in macrophages from atherosclerotic mice: protective role of antioxidants and of paraoxonase. Atherosclerosis 161(2):307–316CrossRefPubMed
go back to reference Galea J, Armstrong J, Gadsdon P, Holden H, Francis SE, Holt CM (1996) Interleukin-1 beta in coronary arteries of patients with ischemic heart disease. Arterioscler Thromb Vasc Biol 16(8):1000–1006CrossRefPubMed Galea J, Armstrong J, Gadsdon P, Holden H, Francis SE, Holt CM (1996) Interleukin-1 beta in coronary arteries of patients with ischemic heart disease. Arterioscler Thromb Vasc Biol 16(8):1000–1006CrossRefPubMed
go back to reference Grebe A, Hoss F, Latz E (2018) NLRP3 inflammasome and the IL-1 pathway in atherosclerosis. Circ Res 122(12):1722–1740CrossRefPubMed Grebe A, Hoss F, Latz E (2018) NLRP3 inflammasome and the IL-1 pathway in atherosclerosis. Circ Res 122(12):1722–1740CrossRefPubMed
go back to reference Groenen AG, Halmos B, Tall AR, Westerterp M (2021) Cholesterol efflux pathways, inflammation, and atherosclerosis. Crit Rev Biochem Mol Biol 56(4):426–439CrossRefPubMedPubMedCentral Groenen AG, Halmos B, Tall AR, Westerterp M (2021) Cholesterol efflux pathways, inflammation, and atherosclerosis. Crit Rev Biochem Mol Biol 56(4):426–439CrossRefPubMedPubMedCentral
go back to reference Gross O, Thomas CJ, Guarda G, Tschopp J (2011) The inflammasome: an integrated view. Immunol Rev 243(1):136–151CrossRefPubMed Gross O, Thomas CJ, Guarda G, Tschopp J (2011) The inflammasome: an integrated view. Immunol Rev 243(1):136–151CrossRefPubMed
go back to reference He H, Jiang H, Chen Y, Ye J, Wang A, Wang C, Liu Q, Liang G, Deng X, Jiang W, Zhou R (2018) Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity. Nat Commun 9(1):2550CrossRefPubMedPubMedCentral He H, Jiang H, Chen Y, Ye J, Wang A, Wang C, Liu Q, Liang G, Deng X, Jiang W, Zhou R (2018) Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity. Nat Commun 9(1):2550CrossRefPubMedPubMedCentral
go back to reference Hu Q, Zhang T, Yi L, Zhou X, Mi M (2018) Dihydromyricetin inhibits NLRP3 inflammasome-dependent pyroptosis by activating the Nrf2 signaling pathway in vascular endothelial cells. BioFactors 44(2):123–136CrossRefPubMed Hu Q, Zhang T, Yi L, Zhou X, Mi M (2018) Dihydromyricetin inhibits NLRP3 inflammasome-dependent pyroptosis by activating the Nrf2 signaling pathway in vascular endothelial cells. BioFactors 44(2):123–136CrossRefPubMed
go back to reference Hybertson BM, Gao B, Bose SK, McCord JM (2011) Oxidative stress in health and disease: the therapeutic potential of Nrf2 activation. Mol Asp Med 32(4–6):234–246CrossRef Hybertson BM, Gao B, Bose SK, McCord JM (2011) Oxidative stress in health and disease: the therapeutic potential of Nrf2 activation. Mol Asp Med 32(4–6):234–246CrossRef
go back to reference Liu W, Yin Y, Zhou Z, He M, Dai Y (2014) OxLDL-induced IL-1 beta secretion promoting foam cells formation was mainly via CD36 mediated ROS production leading to NLRP3 inflammasome activation. Inflamm Res 63(1):33–43CrossRefPubMed Liu W, Yin Y, Zhou Z, He M, Dai Y (2014) OxLDL-induced IL-1 beta secretion promoting foam cells formation was mainly via CD36 mediated ROS production leading to NLRP3 inflammasome activation. Inflamm Res 63(1):33–43CrossRefPubMed
go back to reference Lu C, Chen C, Chen A, Wu Y, Wen J, Huang F, Zeng Z (2020) Oridonin attenuates myocardial ischemia/reperfusion injury via downregulating oxidative stress and NLRP3 inflammasome pathway in mice. Evid Based Complement Alternat Med 2020:7395187CrossRefPubMedPubMedCentral Lu C, Chen C, Chen A, Wu Y, Wen J, Huang F, Zeng Z (2020) Oridonin attenuates myocardial ischemia/reperfusion injury via downregulating oxidative stress and NLRP3 inflammasome pathway in mice. Evid Based Complement Alternat Med 2020:7395187CrossRefPubMedPubMedCentral
go back to reference Ma S, Chen J, Feng J, Zhang R, Fan M, Han D, Li X, Li C, Ren J, Wang Y, Cao F (2018) Melatonin ameliorates the progression of atherosclerosis via mitophagy activation and NLRP3 inflammasome inhibition. Oxid Med Cell Longev 2018:9286458CrossRefPubMedPubMedCentral Ma S, Chen J, Feng J, Zhang R, Fan M, Han D, Li X, Li C, Ren J, Wang Y, Cao F (2018) Melatonin ameliorates the progression of atherosclerosis via mitophagy activation and NLRP3 inflammasome inhibition. Oxid Med Cell Longev 2018:9286458CrossRefPubMedPubMedCentral
go back to reference Martinon F, Burns K, Tschopp J (2002) The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 10(2):417–426CrossRefPubMed Martinon F, Burns K, Tschopp J (2002) The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 10(2):417–426CrossRefPubMed
go back to reference Nguyen T, Sherratt PJ, Huang HC, Yang CS, Pickett CB (2003) Increased protein stability as a mechanism that enhances Nrf2-mediated transcriptional activation of the antioxidant response element. Degradation of Nrf2 by the 26 S proteasome. J Biol Chem 278(7):4536–4541CrossRefPubMed Nguyen T, Sherratt PJ, Huang HC, Yang CS, Pickett CB (2003) Increased protein stability as a mechanism that enhances Nrf2-mediated transcriptional activation of the antioxidant response element. Degradation of Nrf2 by the 26 S proteasome. J Biol Chem 278(7):4536–4541CrossRefPubMed
go back to reference Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377(12):1119–1131CrossRefPubMed Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377(12):1119–1131CrossRefPubMed
go back to reference Roth GA, Mensah GA, Fuster V (2020) The global burden of cardiovascular diseases and risks: a compass for global action. J Am Coll Cardiol 76(25):2980–2981CrossRefPubMed Roth GA, Mensah GA, Fuster V (2020) The global burden of cardiovascular diseases and risks: a compass for global action. J Am Coll Cardiol 76(25):2980–2981CrossRefPubMed
go back to reference Satish M, Agrawal DK (2020) Atherothrombosis and the NLRP3 inflammasome—endogenous mechanisms of inhibition. Transl Res 215:75–85CrossRefPubMed Satish M, Agrawal DK (2020) Atherothrombosis and the NLRP3 inflammasome—endogenous mechanisms of inhibition. Transl Res 215:75–85CrossRefPubMed
go back to reference Shao B-Z, Xu H-Y, Zhao Y-C, Zheng X-R, Wang F, Zhao G-R (2022) NLRP3 inflammasome in atherosclerosis: putting out the fire of inflammation. Inflammation 46(1):35–46CrossRefPubMed Shao B-Z, Xu H-Y, Zhao Y-C, Zheng X-R, Wang F, Zhao G-R (2022) NLRP3 inflammasome in atherosclerosis: putting out the fire of inflammation. Inflammation 46(1):35–46CrossRefPubMed
go back to reference Tkachev VO, Menshchikova EB, Zenkov NK (2011) Mechanism of the Nrf2/Keap1/ARE signaling system. Biochemistry (mosc) 76(4):407–422CrossRefPubMed Tkachev VO, Menshchikova EB, Zenkov NK (2011) Mechanism of the Nrf2/Keap1/ARE signaling system. Biochemistry (mosc) 76(4):407–422CrossRefPubMed
go back to reference Wang JC, Bennett M (2012) Aging and atherosclerosis: mechanisms, functional consequences, and potential therapeutics for cellular senescence. Circ Res 111(2):245–259CrossRefPubMed Wang JC, Bennett M (2012) Aging and atherosclerosis: mechanisms, functional consequences, and potential therapeutics for cellular senescence. Circ Res 111(2):245–259CrossRefPubMed
go back to reference Yan C, Yan H, Mao J, Liu Y, Xu L, Zhao H, Shen J, Cao Y, Gao Y, Li K, Jin W (2020) Neuroprotective effect of oridonin on traumatic brain injury via inhibiting NLRP3 inflammasome in experimental mice. Front Neurosci 14:557170CrossRefPubMedPubMedCentral Yan C, Yan H, Mao J, Liu Y, Xu L, Zhao H, Shen J, Cao Y, Gao Y, Li K, Jin W (2020) Neuroprotective effect of oridonin on traumatic brain injury via inhibiting NLRP3 inflammasome in experimental mice. Front Neurosci 14:557170CrossRefPubMedPubMedCentral
go back to reference Yang H, Huang J, Gao Y, Wen Z, Peng L, Ci X (2020) Oridonin attenuates carrageenan-induced pleurisy via activation of the KEAP-1/Nrf2 pathway and inhibition of the TXNIP/NLRP3 and NF-κB pathway in mice. Inflammopharmacology 28(2):513–523CrossRefPubMed Yang H, Huang J, Gao Y, Wen Z, Peng L, Ci X (2020) Oridonin attenuates carrageenan-induced pleurisy via activation of the KEAP-1/Nrf2 pathway and inhibition of the TXNIP/NLRP3 and NF-κB pathway in mice. Inflammopharmacology 28(2):513–523CrossRefPubMed
go back to reference Yang H, Lv H, Li H, Ci X, Peng L (2019) Oridonin protects LPS-induced acute lung injury by modulating Nrf2-mediated oxidative stress and Nrf2-independent NLRP3 and NF-kappaB pathways. Cell Commun Signal 17(1):62CrossRefPubMedPubMedCentral Yang H, Lv H, Li H, Ci X, Peng L (2019) Oridonin protects LPS-induced acute lung injury by modulating Nrf2-mediated oxidative stress and Nrf2-independent NLRP3 and NF-kappaB pathways. Cell Commun Signal 17(1):62CrossRefPubMedPubMedCentral
go back to reference Yvan-Charvet L, Bonacina F, Guinamard RR, Norata GD (2019) Immunometabolic function of cholesterol in cardiovascular disease and beyond. Cardiovasc Res 115(9):1393–1407CrossRefPubMed Yvan-Charvet L, Bonacina F, Guinamard RR, Norata GD (2019) Immunometabolic function of cholesterol in cardiovascular disease and beyond. Cardiovasc Res 115(9):1393–1407CrossRefPubMed
go back to reference Zhao J, Wang Z, Yuan Z, Lv S, Su Q (2020) Baicalin ameliorates atherosclerosis by inhibiting NLRP3 inflammasome in apolipoprotein E-deficient mice. Diab Vasc Dis Res 17(6):1479164120977441CrossRefPubMedPubMedCentral Zhao J, Wang Z, Yuan Z, Lv S, Su Q (2020) Baicalin ameliorates atherosclerosis by inhibiting NLRP3 inflammasome in apolipoprotein E-deficient mice. Diab Vasc Dis Res 17(6):1479164120977441CrossRefPubMedPubMedCentral
go back to reference Zhao X, Liu Y, Wang L, Yan C, Liu H, Zhang W, Zhao H, Cheng C, Chen Z, Xu T, Li K, Cai J, Qiao T (2022) Oridonin attenuates hind limb ischemia-reperfusion injury by modulating Nrf2-mediated oxidative stress and NLRP3-mediated inflammation. J Ethnopharmacol 292:115206CrossRefPubMed Zhao X, Liu Y, Wang L, Yan C, Liu H, Zhang W, Zhao H, Cheng C, Chen Z, Xu T, Li K, Cai J, Qiao T (2022) Oridonin attenuates hind limb ischemia-reperfusion injury by modulating Nrf2-mediated oxidative stress and NLRP3-mediated inflammation. J Ethnopharmacol 292:115206CrossRefPubMed
go back to reference Zheng F, Xing S, Gong Z, Mu W, Xing Q (2014) Silence of NLRP3 suppresses atherosclerosis and stabilizes plaques in apolipoprotein E-deficient mice. Mediat Inflamm 2014:507208CrossRef Zheng F, Xing S, Gong Z, Mu W, Xing Q (2014) Silence of NLRP3 suppresses atherosclerosis and stabilizes plaques in apolipoprotein E-deficient mice. Mediat Inflamm 2014:507208CrossRef
Metadata
Title
Oridonin attenuates the progression of atherosclerosis by inhibiting NLRP3 and activating Nrf2 in apolipoprotein E-deficient mice
Authors
Lei Wang
Xiaoqi Zhao
Jiawen Ding
Yutong Liu
Han Liu
Lei Zheng
Hongting Zhao
Zichen Sun
Kuanyu Li
Jing Cai
Tong Qiao
Publication date
08-05-2023
Publisher
Springer International Publishing
Published in
Inflammopharmacology / Issue 4/2023
Print ISSN: 0925-4692
Electronic ISSN: 1568-5608
DOI
https://doi.org/10.1007/s10787-023-01161-9

Other articles of this Issue 4/2023

Inflammopharmacology 4/2023 Go to the issue